期刊文献+

前列腺特异性膜抗原和前列腺特异性抗原表达强度与前列腺癌Gleason评分之间的相关性研究 被引量:5

Correlation study of expression levels of prostate-specific membrane antigen and prostate-specific antigen with Gleason score of prostate carcinoma
原文传递
导出
摘要 目的研究前列腺特异性膜抗原(PSMA)和前列腺特异性抗原(PSA)的表达强度与前列腺癌Gleason评分之间的相关性。方法制备抗PSMA膜外段表位的单克隆抗体,应用免疫组织化学方法检测前列腺癌中PSMA的表达,统计分析其与Gleason评分之间的相关性,并和PSA与Gleason评分之间的相关性进行对比。结果制备出8株分泌抗PSMA膜外段表位的单抗的杂交瘤细胞株。免疫组化结果表明,PSMA的表达强度与前列腺癌的Gleason评分之间存在相关性。在分化差的前列腺癌中,PSMA水平高于分化中等和分化良好的前列腺癌(P<0.01),而PSA在前列腺癌中的表达无明显差异(P>0.05)。结论PSMA表达水平在分化差的前列腺癌中明显升高,与Gleason评分存在相关性,可以作为前列腺癌的Gleason分级的标记物,提示PSMA可以作为对激素疗法效果不敏感的低分化前列腺癌抗体介导的免疫治疗靶点。 Objective To study the correlation of prostate-specific membrane antigen(PSMA) and prostate-specific antigen (PSA) expression with Gleason score of prostate carcinoma. Methods Monoclonal antibodies against epitopes of PSMA extracellular domain were prepared, with which the expression of PSMA of prostate carcinoma (PC) was determined by immunohistochemical staining. Correlation of its expression with Gleason score of PC was statistically analyzed, and compared with that of PSA. Results Eight hybridoma cell lines secreting monoclonal antibodies specific for PSMA were prepared. PSMA expression level was positively correlated with Gleason score. In poorly differentiated prostate carcinoma, the expression intensity of PSMA was higher than that of medium-and well-differentiated prostate carcinoma (P<0.01). However, there was no correlation between level of PSA expression and Gleason score (P>0.05). Conclusion PSMA expression level may be used as a useful surrogate marker in Gleason grading of prostate carcinoma. It may be a more suitable target than PSA in antibody mediated immunotherapy against poorly differentiated prostate carcinoma which is usually not sensitive to hormonal therapy.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2004年第12期735-738,共4页 Chinese Journal of Oncology
关键词 前列腺肿瘤 前列腺特异性膜抗原 前列腺特异性抗原 免疫组织化学 Prostate neoplasms PSMA PSA immunohistochemical Gleason grading
  • 相关文献

参考文献8

  • 1任加强,郑莉,陈琦,李华,张敏,张膺宇,张秀荣,朱虹光.抗PSMA膜外段单克隆抗体的制备及其初步应用[J].复旦学报(医学版),2003,30(4):330-332. 被引量:3
  • 2Aihara M;Lebovit;RM;Wheeler TM.Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer,1994.
  • 3Chang SS;Reuter VE;Heston WD.Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma[J],2001(6).
  • 4Xiao Z;Adam BL;Cazares LH.Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease[J],2001.
  • 5Lapidus RG;Tiffany CW;Isaacs JT.Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells,2000.
  • 6Grauer LS;Lawler KD;Marignac JL.Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM′ protein in the LNCaP prostatic carcinoma cell line,1998.
  • 7Bostwick DG;Pacelli A;Blute M.Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases[J],1998(11).
  • 8马洁,曹利人.包裹外毒素Ⅲ的抗CD19脂质体靶向杀伤人B淋巴瘤[J].中华肿瘤杂志,2003,25(1):36-38. 被引量:7

二级参考文献16

  • 1Pastan I, FitzGerald D. Recombinant toxins for cancer treatment.Science, 1991,254:1173-1177.
  • 2Allen TM, Ahmad I, Lopes de Menezes DE, et al. Immtmoliposome-mediated targeting of anti-cancer drugs in vivo. Biochem Soc Trans,1995, 23: 1073-1079.
  • 3Allen TM, Moase EH. Therapeutic opportunities for targeted lipesomal drug delivery. Adv Drug Del Rev, 1996, 21:117-133.
  • 4MaClean AL, Symonds G, Ward R. Immunoliposomes as targeted delivery vehicles for cancer therapeutics, Int J Oncol, 1997, 11 : 325-332.
  • 5Lasic DD, Papahadjopoulos D. Liposomes revisited. Science, 1995,267: 1275-1276.
  • 6Moil A, Klibanov AL, Torchilin VP, et al. Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett, 1991, 284: 263-266.
  • 7Lopes de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.Cancer Res, 1998, 58: 3320-3330.
  • 8Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma:a study of 184 cases. Cancer, 1998,82:2256.
  • 9Sweat SD, Pacelli A, Murphy GP, et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology, 1998,52:637.
  • 10Xiao Z, Adam BL, Cazares LH, et al. Quantitation of serum prostatespecific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res,2001,61 : 6029.

共引文献8

同被引文献85

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部